GHK-Cu: The Copper Signal in the Repair Matrix

The short version

GHK-Cu is a very small peptide — three amino acids (glycine, histidine, lysine) — bound to a single copper ion. The same GHK sequence appears naturally inside type I collagen, the main structural protein of skin and tendon. That lineage is a clue to its function: at low concentrations it signals the fibroblasts in your dermis to rebuild their scaffolding of collagen and elastin ^[4][6].

Of the two peptides on this desk, GHK-Cu has by far the most human evidence. A 2025 review of clinical trials found it raised procollagen synthesis in 70% of treated subjects, outperforming both vitamin C (50%) and retinoic acid (40%) in the same comparison ^[1]. A controlled 6-month trial in 45 men saw significant hair-count increases with a GHK-containing topical versus placebo ^[3]. The catch is also baked into the chemistry: the bare GHK tripeptide has a cLogP of -2.24, which means it crosses intact skin poorly on its own. Topical copper-peptide cosmetics are legal and widely sold; injectable or systemic use is unapproved and research-only ^[1]. This page summarizes the studies and recommends no dose or regimen.

What it is

GHK-Cu is a linear tripeptide — glycyl-L-histidyl-L-lysine — chelated one-to-one with a copper(II) ion. The copper is coordinated through the histidine imidazole nitrogen, the glycine alpha-amino nitrogen, and the deprotonated glycine-histidine backbone amide nitrogen; the lysine side chain is left free. The complex carries a small positive charge (molecular formula C14H23CuN6O4+, MW approximately 402.9 Da, CAS 89030-95-5). The identical GHK sequence occurs endogenously within the alpha-2(I) chain of type I collagen and in the matrix protein SPARC/osteonectin — the body already uses this motif, and the copper coordination is required for most of its reported biological activity ^[4].

How it works

GHK-Cu operates as both a copper chaperone (delivering copper to sites of repair) and a broad signaling molecule. At picomolar-to-nanomolar concentrations it directly stimulates dermal fibroblasts to synthesize collagen, elastin, glycosaminoglycans and the proteoglycan decorin, while rebalancing matrix metalloproteinases against their TIMP inhibitors — the enzymes that build the matrix alongside the enzymes that keep it dynamic ^[6]. The copper ion itself enables lysyl oxidase-mediated cross-linking that physically knits collagen and elastin strands together, plus a superoxide-dismutase-like antioxidant action.

At the gene level, a Connectivity Map analysis reported that GHK shifts expression of approximately 31.2% of human genes at a 50%-or-greater change threshold — roughly 59% of those genes up and 41% down — with strong stimulation of the ubiquitin-proteasome system (41 genes up, 1 down), DNA-repair gene sets, and antioxidant programs ^[2]. One correction belongs here: the widely repeated "~4,000 genes" figure is an extrapolation; the verified 50%-threshold table covers on the order of 2,100 genes ^[2].

What the research shows

Collagen synthesis: cell culture. The foundational in vitro study showed that GHK-Cu stimulated collagen synthesis in human fibroblast cultures in a dose-dependent way: stimulation began between 10^-12 and 10^-11 M, maximized at 10^-9 M, and was independent of any change in cell number ^[7]. This established GHK-Cu as a specific metabolic signal, not a cell-proliferation effect.

Skin regeneration: review of clinical trials. The 2015 canonical review documents GHK-Cu stimulating collagen, dermatan sulfate, chondroitin sulfate and decorin synthesis, notes that plasma GHK declines from roughly 200 ng/mL at age 20 to roughly 80 ng/mL by age 60, and reports that topical GHK-Cu increased collagen production in 70% of treated women versus 50% for vitamin C and 40% for retinoic acid, with documented placebo-controlled improvements in skin laxity, clarity, fine lines, wrinkle depth and density ^[4].

Tissue remodeling: multi-model review. A 2008 review covering human and animal studies catalogues GHK-Cu's full profile: increased protein synthesis of collagen, elastin, metalloproteinases, anti-proteases, VEGF, FGF-2, NGF, neurotrophins 3 and 4, and erythropoietin, alongside suppression of free radicals, TGF-beta-1, TNF-alpha and protein glycation, and chemoattraction of macrophages, mast cells and capillary cells ^[6].

Hair growth: controlled human trial. In a 6-month RCT of 45 men with androgenetic alopecia, a complex of 5-aminolevulinic acid and glycyl-histidyl-lysine peptide increased hair count by 52.6 at 100 mg/mL and 71.5 at 50 mg/mL, versus only 9.6 for placebo (p<0.05), with no adverse events in any group ^[3]. This is the most controlled human efficacy signal for a GHK-containing topical — though the product was a combination, not pure GHK-Cu.

Delivery science: the permeability problem. A 2025 review confirms that GHK's poor stratum-corneum permeability (cLogP -2.24) is the central challenge for topical formulations. Enhancement strategies include palmitoylation (cLogP improved to 1.14) and microneedle pretreatment, which raised permeation from essentially zero through intact skin to approximately 134 nmol GHK ^[1]. A separate ex vivo human skin-penetration study quantified GHK-Cu delivery: a permeability coefficient of 2.43 +/- 0.51 x 10^-4 cm/h, with 136.2 +/- 17.5 ug/cm^2 permeating over 48 hours and 97 +/- 6.6 ug/cm^2 retained as a measurable dermal copper depot ^[5].

Reported effects, cautions & safety

Topical copper-peptide products carry a long real-world cosmetic safety record, and injectable use carries risks that are explicitly uncharacterized in humans. The literature anchors several specific cautions:

• No approved drug indication. There is no FDA- or EMA-approved GHK-Cu therapeutic product by any route. Topical Copper Tripeptide-1 is a legal cosmetic ingredient in the US, EU and UK; injectable or systemic use is unapproved and research-only ^[1].
• WADA. GHK-Cu is not currently itemized on the WADA Prohibited List as of the 2024-2025 versions, but the catch-all S0 category can cover non-approved pharmacological substances; verify the current list before any athletic-research context.
• Localized hyperpigmentation. Skin darkening has been reported with some topical copper-peptide protocols — approximately 40% in one acne-scar microneedling study. A CO2-laser post-procedure RCT (n=13) found no objective skin benefit despite higher patient satisfaction.
• Vitamin C / acid incompatibility. Cu(II) reduction or copper competition can destroy both GHK-Cu and co-applied vitamin C or low-pH acid actives — a real formulation and user-error risk.
• Theoretical copper accumulation. Prolonged systemic use raises a theoretical concern around copper-zinc balance; no human copper-toxicity cases attributed to GHK-Cu appear in the peer-reviewed record, but human systemic pharmacokinetics are unvalidated.
• Single-investigator origin. A large share of foundational GHK-Cu mechanistic and review literature originates from a single investigator and colleagues ^[2][4][6], which limits independent replication of the broader gene-expression and anti-aging claims.

Where it fits in skin research

GHK-Cu is the evidence anchor on this desk. It holds the most human data, the clearest dose-response signal in cell culture ^[7], and the longest topical cosmetic safety record. What it lacks is validated systemic human pharmacokinetics — so community claims about injectable GHK-Cu dosing regimens have no peer-reviewed basis ^[1]. The GLOW blend builds on GHK-Cu's matrix-remodeling profile by combining it with two tissue-repair peptides, but the combination introduces trade-offs: added regulatory exposure (WADA status from the TB-500 component) and zero combination safety data. Compare the two side by side for the clearest contrast.